论文部分内容阅读
目的研究不同佐剂与鼠疫F1-V融合重组蛋白抗原滴鼻免疫Balb/c小鼠,观察机体产生体液免疫和局部粘膜免疫反应的效果,为发展黏膜疫苗提供理论基础。方法鼠疫F1-V融合重组蛋白抗原按比例分别与PorB(2类外膜蛋白)重组蛋白、蛋白体佐剂制备黏膜疫苗,滴鼻免疫Balb/c小鼠3次,取尾静脉血,采用ELISA检测血清IgG及抗体亚型分类,并检测鼻咽、肺、小肠及阴道灌洗液sIgA;采用FAC检测脾淋巴细胞表型的变化。结果PorB重组蛋白佐剂疫苗组和蛋白体佐剂疫苗组较无佐剂组体液免疫抗体水平高、蛋白体佐剂疫苗组好于PorB重组蛋白佐剂疫苗组,但无显著性差异。结论PorB重组蛋白佐剂疫苗和蛋白体佐剂疫苗均能诱导较强的系统免疫和黏膜免疫应答,且PorB重组蛋白佐剂疫苗免疫效果可与蛋白体佐剂疫苗相媲美,可进一步论证是否可用PorB重组蛋白佐剂替代蛋白体佐剂,这为鼠疫粘膜疫苗的研制奠定了基础。
Objective To study the effect of humoral and local mucosal immune response induced by different adjuvants and placenta F1-V fusion protein antigens in nasal Balb / c mice to provide theoretical basis for the development of mucosal vaccine. Methods The plague F1-V fusion protein antigen was used to prepare the mucosal vaccine with PorB (type 2 outer membrane protein) recombinant protein and protein adjuvant respectively. Balb / c mice were immunized three times intranasally and the tail vein blood was obtained. ELISA Serum IgG and antibody subtypes were detected, sIgA in nasopharynx, lung, small intestine and vaginal lavage fluid were detected. FACS was used to detect the phenotype of splenic lymphocytes. Results The PorB recombinant protein adjuvanted vaccine group and the protein adjuvant vaccine group had higher levels of humoral immune antibody than the non-adjuvanted vaccine group, while the Porcine adjuvanted vaccine group was better than the PorB recombinant protein adjuvanted vaccine group, but no significant difference was found. Conclusions PorB recombinant protein adjuvant vaccine and protein adjuvant vaccine can induce strong systemic and mucosal immune responses, and PorB recombinant protein adjuvant vaccine can be compared with the protein adjuvant vaccine to further prove whether it is available PorB recombinant protein adjuvant instead of the protein body adjuvant, which laid the foundation for the development of plague vaccine.